Using CATE values to divide the combined study cohorts with estimator information (46,394 individuals) into sub-cohorts revealed that those with a greater estimated glycemic advantage with glucagon-lile-peptide-1 receptor agonists over SGLT2 inhibitors were predominantly older and female, with lower initial HbA1c, body mass index (BMI), and estimated glomerular filtration rate (eGFR)
The glucose-lowering efficacy measured by the decrease in HbA1c was dose-dependent in the tirzepatide group and did not plateau [52]
The honest gap: this high-quality evidence applies to the approved, pharmaceutical-grade product used under medical supervision
What to eat while using GLP-1 GIP B12 Nutrition during tirzepatide therapy requires more attention than most patients expect
Cardiovascular biology of the incretin system
GLP-1 medications carry important warnings and contraindications, including a boxed warning for thyroid C-cell tumors in rodents (contraindicated in patients with personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2)
